Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 13/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | TOP2A | P11388 | 2/20 | 0.50 |
| ▸ | TOP2B | Q02880 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23901782 | 0.97 | NISCH (0.58) | NISCHGAATSHRMAOBTOP2A | |
| SCHEMBL23902144 | 0.94 | MAOB (0.60) | NISCHMAOBTOP2ATOP2BLMNA | |
| SCHEMBL23902187 | 0.85 | NISCH (0.46) | NISCHGAATSHRMAOBTOP2A | |
| SCHEMBL15788088 | 0.85 | MAOB (0.74) | NISCHMAOB | |
| SCHEMBL8195812 | 0.85 | NISCH (0.71) | NISCHGAATSHRMAOBTOP2A | |
| SCHEMBL23902145 | 0.82 | MAOB (0.48) | NISCHMAOBLMNARECQL | |
| SCHEMBL13327264 | 0.78 | NISCH (0.81) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL14029044 | 0.74 | NISCH (0.75) | NISCHGAATSHRMAOBTOP2A | |
| SCHEMBL23902307 | 0.74 | NISCH (0.60) | NISCHGAATSHRTOP2ATOP2B | |
| SCHEMBL23902308 | 0.74 | NISCH (0.55) | NISCHGAATSHRTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2021-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210309641-A1 | AMIDINES AND AMIDINE ANALOGS FOR THE TREATMENT OF BACTERIAL INFECTIONS AND POTENTIATION ANTIBIOTICS | PAM, AMPD1, AMPD3 | NISCH 24/4885GAA 885/4885TSHR 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.